FDA: Weight-control drug lorcaserin may raise cancer risk

FDA: weight control drug lorcaserin may raise cancer risk

The prescription weight control medicine lorcaserin (Belviq, Belviq XR) may increase the risk for cancer, according to the results of a clinical trial assessing the safety of the drug, the U.S. Food and Drug Administration says.

The agency said, "[W]e cannot conclude that lorcaserin contributes to the " but "wanted to make the public aware of this potential risk. We are continuing to evaluate the clinical trial results and will communicate our final conclusions and recommendations when we have completed our review."

Health care providers should balance the benefits of taking lorcaserin against the potential risks when deciding whether to prescribe or continue patients on the medication, the FDA advised. It said that patients currently taking lorcaserin should talk to their about the potential increased risk for cancer with use of the medication.

Lorcaserin is approved for use with a reduced-calorie diet and increased to help weight loss in adults who are obese or are overweight and have weight-related medical problems. Lorcaserin increases feelings of fullness so that people eat less. It is available as a tablet (Belviq) and an extended-release tablet (Belviq XR).


Explore further

Are weight loss drugs the next tool to combat cocaine addiction?

More information: More Information

Copyright © 2020 HealthDay. All rights reserved.

Citation: FDA: Weight-control drug lorcaserin may raise cancer risk (2020, January 16) retrieved 22 January 2020 from https://medicalxpress.com/news/2020-01-fda-weight-control-drug-lorcaserin-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments